Skip to main content
Premium Trial:

Request an Annual Quote

Reprogenetics, Illumina Collaborate on NGS-based IVF Technologies

NEW YORK (GenomeWeb) – Preimplantation genetics laboratory Reprogenetics today announced a deal with Illumina as its preferred partner for the development of next-generation sequencing-based in vitro fertilization technologies.

Reprogenetics will expand its current array-based preimplantation genetic screening service to one using Illumina's VeriSeq PGS, a kit that leverages NGS to screen all 24 chromosomes to identify embryos with the greatest potential of producing a viable pregnancy. The Livingston, NJ-based company added that it will lead research collaborations with Illumina to investigate the accuracy of NGS protocols and to conduct randomized clinical trials in subsets of patients who are candidates for comprehensive chromosome screening.

The use of Illumina's technologies will allow Reprogenetics to maximize the potential of NGS-based technologies for preimplantation genetic screening, preimplantation genetic diagnosis, and infertility in its laboratories worldwide, Reprogenetics said.

Financial and other terms of the deal were not disclosed.

"By combining our more than 20 years of expertise in preimplantation screening and diagnosis with Illumina's cutting-edge NGS platform, we have the right tools to deliver breakthroughs that improve the likelihood of positive pregnancy outcomes," Reprogenetics Founder and Director Santiago Munne said in a statement.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.